Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 2/2014

01-03-2014 | Editorial

50 years of newborn screening

Authors: Georg F. Hoffmann, Martin Lindner, J. Gerard Loeber

Published in: Journal of Inherited Metabolic Disease | Issue 2/2014

Login to get access

Excerpt

Half a century ago Robert Guthrie published his seminal paper on newborn screening for phenylketonuria. Few of us will remember these early years and the difficulties encountered by Bob and his then few followers. The period was wonderfully summarized by him in the journal Screening in 1992 (volume 1, pages 5–15). From the 1960s to the end of the last century newborn screening progressed steadily with some technical advances and consolidated professional structures. Just before the turn of the century, highly sophisticated high-throughput multiple-analytes platforms (ELISAs, tandem MS, DNA, etc.) were developed and adapted for use in newborn screening. Particularly the applications of tandem mass spectrometry, paralleled by advances in molecular medicine, have now brought screening very much to center stage of scientific, medical and ethical issues. The Joint Meeting of the APHL Newborn Screening and Genetic Testing Symposium and the International Society for Neonatal Screening, held in Atlanta, Georgia, USA in May 2013, combined looking back and drawing from the experience of 50 years with a comprehensive coverage of today´s hot topics. This issue of the journal draws on the material presented. …
Metadata
Title
50 years of newborn screening
Authors
Georg F. Hoffmann
Martin Lindner
J. Gerard Loeber
Publication date
01-03-2014
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 2/2014
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-014-9688-5

Other articles of this Issue 2/2014

Journal of Inherited Metabolic Disease 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine